Perritt Capital Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Perritt Capital Management’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-12,000	Closed	-$88.8K	–	305
2024 Q2	$88.8K	Hold	12,000	–	–	0.05%	201
2024 Q1	$94K	Hold	12,000	–	–	0.05%	196
2023 Q4	$61K	Hold	12,000	–	–	0.03%	209
2023 Q3	$71K	Hold	12,000	–	–	0.04%	199
2023 Q2	$89K	Hold	12,000	–	–	0.05%	203
2023 Q1	$113K	Hold	12,000	–	–	0.06%	180
2022 Q4	$128K	Hold	12,000	–	–	0.07%	182
2022 Q3	$89K	Hold	12,000	–	–	0.06%	177
2022 Q2	$58K	Buy	+12,000	New	+$68.1K	0.04%	179

Other funds holding ATNM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Los Angeles Capital Management Los Angeles, California $25.4B AUM 38.46% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Perritt Capital Management's ATNM Position: Q3 2024 in Review

Perritt Capital Management sold out of Actinium Pharmaceuticals (ATNM) in Q3 2024, closing a stake of 12,000 shares — an estimated $88.8K sold.

Perritt Capital Management first reported a position in ATNM in Q2 2022 and held it in 9 quarters. The position peaked at $128K in Q4 2022. 72 funds tracked by Wall St. Rank hold ATNM as of Q3 2024.

Perritt Capital Management reported no remaining Actinium Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Perritt Capital Management sold 12,000 Actinium Pharmaceuticals shares in Q3 2024, an estimated $88.8K.
Perritt Capital Management first reported a position in Actinium Pharmaceuticals in Q2 2022 and held it in 9 quarters.
Perritt Capital Management's Actinium Pharmaceuticals position peaked at $128K in Q4 2022.
72 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2024.

Based on Perritt Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.